Table 2 Summary of primary HCC treated SBRT with or without transarterial chemoembolization
No | Age | Sex | Tumor site | Tumor volume (cc) | SBRT dose (Gy) | Response | Status (months) |
|---|---|---|---|---|---|---|---|
1 | 59 | F | Right lobe | 25.0 | 30 | PR | DOI(2.0) |
2 | 63 | F | Right lobe | 5.4 | 36 | CR | NED(18.5) |
3 | 52 | F | Right lobe | 28.6 | 30 | PR | A&D(16.0) |
4 | 57 | F | Right lobe | 23.5 | 36 | CR | NED(14.5) |
5 | 78 | M | Right lobe | 26.5 | 36 | CR | NED(14.0) |
6 | 56 | F | Right lobe | 31.9 | 36 | PR | A&D(13.0) |
7 | 75 | M | Right lobe | 25.2/27.5 | 39/36 | SD/CR | A&D(13.0) |
8 | 60 | M | Right lobe | 36.5 | 36 | PR | A&D(12.5) |
9 | 56 | M | Left lobe | 15.4 | 36 | CR | NED(12.5) |
10 | 70 | F | Right lobe | 16.9 | 36 | SD | A&D(12.0) |
11 | 44 | M | Right lobe | 16.6 | 30 | PR | NED(12.0) |
12 | 48 | M | Right lobe | 35.1 | 30 | SD | A&D(12.0) |
13 | 77 | M | Right lobe | 33.3 | 33 | PR | DOI(11.5) |
14 | 60 | M | Right lobe | 6.9 | 36 | CR | A&D(11.0) |
15 | 55 | M | Right lobe | 12.0 | 36 | PR | A&D(10.0) |
16 | 62 | F | Right lobe | 31.3 | 30 | PR | A&D(9.0) |
17 | 56 | F | Right lobe | 17.6 | 33 | PR | A&D(9.0) |
18 | 62 | M | Right lobe | 21.6 | 30 | SD | A&D(8.5) |
19 | 75 | M | Right lobe | 13.6 | 33 | PR | A&D(8.5) |
20 | 48 | M | Right lobe | 12.0 | 36 | PR | A&D(8.0) |
21 | 62 | M | Right lobe | 57.3 | 30 | PR | A&D(7.5) |
22 | 67 | M | Right lobe | 3.6 | 30 | PR | A&D(6.0) |
23 | 57 | M | Portal vein | 47.7 | 36 | PR | DOM(2.0) |
24 | 60 | M | Portal vein | 16.2 | 36 | PR | NED(15.0) |
25 | 46 | F | Portal vein | 28.3 | 36 | SD | DOI(3.0) |
26 | 71 | F | Portal vein | 3.9 | 30 | SD | A&D(13.0) |
27 | 44 | M | Portal vein | 38.9 | 30 | SD | DOI(12.0) |
28 | 63 | F | Portal vein | 34.7 | 30 | SD | A&D(8.5) |
29 | 55 | M | Portal vein | 37.0 | 30 | CR | NED(8.0) |
30 | 48 | M | Portal vein | 23.7 | 30 | SD | DOI(7.0) |
31 | 57 | F | Portal vein | 32.8 | 30 | PR | A&D(6.0) |